Related News

No related news articles were found.

semperit ag holding (SEM) Related Businessweek News

No Related Businessweek News Found

semperit ag holding (SEM) Details

Semperit Aktiengesellschaft Holding develops, produces, and sells rubber and plastics products worldwide. It operates in four segments: Sempermed, Semperflex, Sempertrans, and Semperform. The Sempermed segment produces and sells examination, protective, and surgical gloves. This segment provides medical examination gloves under the Sempercare brand name for daily use in hospitals and care facilities, as well as in dental and medical practices; and disposable and re-usable gloves under the Semperguard brand name for protection in various areas, such as laboratories, pharmaceuticals, and the food industry, as well as in professional cleaning and hygiene. The Semperflex segment offers hydraulic hoses that are used for the transmission of pressure and energy in heavy-duty machinery, such as excavators and cranes; industrial hoses for industrial and technical requirements; elastomer sheeting to punching companies and technical traders for producing various kinds of seals; and wear-resistant sheeting for lining and others. The Sempertrans segment develops, produces, and distributes textile and steel-cord conveyor belts that are used in mining, steel, cement, and transport industries, as well as in civil engineering and power stations. The Semperform segment provides window and door profiles, elastomer and insulation profiles, escalator handrails, cableway rubber rings, sheaves and bullwheel liners, and rubber foils. The company was founded in 1824 and is headquartered in Vienna, Austria. Semperit Aktiengesellschaft Holding is a subsidiary of B & C Semperit Holding GmbH.

semperit ag holding (SEM) Key Developments

Semperit Aktiengesellschaft Holding Proposes Basic and Special Dividend for 2014; Reports Group Earnings Results for the Full Year Ended December 31, 2014; Provides Group Earnings Guidance for 2015

Mar 26 15

The Management Board of Semperit Aktiengesellschaft Holding will propose a basic dividend of EUR 1.10 per share to the Annual General Meeting for 2014 along with a one-time special dividend of EUR 4.90 per share compared to a basic dividend of EUR 0.90 per share and an anniversary bonus of EUR 0.30 per share for the 2013 financial year.
The company reported group earnings results for the full year ended December 31, 2014. The group showed a satisfactory revenue and earnings development in 2014 in spite of a weak economic climate. Revenue rose 2.6% year-on-year to EUR 930.4 million. This growth can be attributed to strong sales performances and high capacity utilization in both the Medical and Industrial Sectors. This more than compensated for negative price effects related to the ongoing low raw material prices. Double-digit sales growth was generated once again in the Medical Sector, whereas the revenue increase in the more cyclically-dependent Industrial Sector was driven by the strong development of the Semperflex segment. Semperit showed an improvement in EBITDA and EBIT. The group's consolidated EBITDA rose 2.7% from the prior-year level to EUR 136.1 million. EBIT was up slightly by 0.8% to EUR 88.5 million. This growth was due to higher revenue as well as a positive effect relating to the change in consolidation of the Thai joint venture company Siam Sempermed Corp. Ltd. (SSC) from full to at-equity consolidation. Semperit achieved a net result (earnings after tax) of EUR 49.7 million in 2014, down from EUR 54.9 million in 2013, which is attributable to a higher income tax expense from prior periods as well as tax postings related to the previously mentioned change in consolidation. Semperit invested a total of EUR 74.4 million in 2014 against EUR 49.7 million last year, to expand and modernize its production plants.
For 2015, revenue and earnings should remain at an attractively high level but will not match the performance of the past two years as a result of the current economic and raw material price situation as well as the effect of the change in consolidation in 2014. Due to the conversion of the previously full consolidation of the 50% joint venture investment at Siam Sempermed Corp. Ltd., Thailand to the at equity method as at December 31, 2014, the revenue recognized will likely be 10% lower compared to full consolidation and EBIT 20% lower than reported in the past. No significant effects are expected with respect to the earnings after tax and minorities of the Semperit Group as well as on the earnings per Semperit share. Semperit is continuing the expansion of its production capacities in both the Medical Sector and Industrial Sector. CAPEX of approximately EUR 75 million is planned for 2015 against EUR 74 million last year, of which about EUR 50 million relates to growth investments. The additional capacities will gradually become available in the course of the years 2015 and 2016 with correspondingly positive effects on the group's revenue development.

Semperit Aktiengesellschaft Holding - Special Call

Feb 16 15

To discuss the changes in consolidation method for Siam Sempermed Corp. Ltd

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.